补肾化瘀壮骨法治疗老年糖尿病合并骨质疏松症肾虚血瘀证的临床研究
|
摘要
目的：探讨中医学对老年糖尿病合并骨质疏松症的认识,采用补肾化瘀壮骨法治疗老年糖尿病合并骨质疏松症,客观评价补肾化瘀壮骨法对老年糖尿病合并骨质疏松症肾虚血瘀证患者的治疗效果,尤其是对临床症状、血清钙、磷、性激素水平、骨密度测定、细胞因子等方面所产生的影响,并评价其安全性,为临床应用提供客观依据。
方法：采用随机、对照的研究方法,将符合老年糖尿病合并骨质疏松症的患者50例,按1：1对照原则,随机分为对照组和治疗组。在基础治疗和西药常规降糖治疗的基础上,对照组给予钙尔奇D片600mg,每日1次；治疗组给予补肾化瘀壮骨方中药水煎剂,每日1剂,分早晚两次服用。以4周为1个疗程,观察3个疗程。治疗前后两组分别评价其临床症状、体征的变化,治疗前后观测血糖、糖化血红蛋白,骨密度、血清钙、磷,雌二醇、睾酮,白介素-6等指标。全部数据以SPSS16.0统计软件进行统计学分析。
结果：治疗前两组的性别、年龄、病程等基线数据经统计学处理无显着性差异,有可比性(P>0.05)。①对症状体征的改善作用：治疗组患者治疗后中医证候有明显改善,且治疗组改善情况明显优于对照组,有显著性差异(P<0.01)。②降糖效果：治疗后两组患者空腹血糖、餐后血糖均明显降低,与治疗前比较均有显着性差异(P<0.01)；组间比较治疗组空腹血糖改善较对照组有显著性差异(P<0.01),治疗组餐后血糖、糖化血红蛋白改善较对照组有差异(P<0.05)。③改善骨密度(BMD)：治疗后治疗组患者BMD均明显升高,较治疗前有显著性差异(P<0.01)；对照组较治疗前无明显差异(P>0.05)。组间比较治疗组BMD的改善较对照组有差异(P<0.05)。④对血钙、血磷的影响：治疗前两组血钙、血磷比较,无明显差异(P>0.05),具有可比性。治疗后两组患者血钙均有所升高,但差异无统计学意义(P>0.05)；治疗后两组患者血磷均有所降低,但差异无统计学意义(P>0.05)；治疗组血钙、血磷的变化较对照组无显著性差异(P>0.05)。⑤性激素水平：治疗后治疗组男性患者雌二醇(E2)水平下降,雄激素(T)水平升高,较治疗前有显著性差异(P<0.01)。组间比较,治疗组E2水平改善较对照组有差异(P<0.05)；治疗组T水平升高较对照组无差异(P>0.05)。治疗后治疗组女性患者E2水平升高,T水平降低,较治疗前均有显著性差异(P<0.01)。组间比较,治疗组E2水平升高较对照组有差异(P<0.05),T水平降低较对照组无显著性差异(P>0.05)。⑥对白介素-6(IL-6)的影响：治疗后治疗组患者IL-6较治疗前改善有显著性差异(P<0.01)；组间比较治疗组IL-6改善较对照组有差异(P<0.05)。⑦安全性指标：治疗组患者血、尿、粪常规及肝肾功能检查均在正常范围。两组均未见不良反应。
结论：从初步临床研究来看,补肾化瘀壮骨法治疗2型糖尿病骨质疏松症肾虚血瘀证,可明显改善患者的临床症状；在西医学指标方面,可以降低血糖、糖化血红蛋白,改善骨密度,调节性激素水平,且无肝肾功能损害,治疗本病安全、有效,有广泛的应用前景。但由于本人为境外学生,能力和条件限制,本研究病例数相对较少,今后需进一步深入研究。
Purpose:To discuss the understanding of Traditional Chinese Medicine about type-2diabetes with osteoporosis, using the therapy of renal-vital-reinforce and bone-vital-strong prescription to treat type-2diabetes with osteoporosis.To observe the therapeutic efficacy of this prescription in treating type-2diabetes with osteoporosis liver-kidney deficiency symptoms by the indexes such as clinical symptoms,hormones,cytokines,bone mineral density.Then evaluate its curative effect and safety, so as to guide its clinical application
Methods:A randomized,controlled trial was conducted.The patients of type-2diabetes with osteoporosis were randomly classified into two groups according to1:1paired matched.On the basic of normal treatment and western medicine, the patients of treated group were treated by Chinese medicine while the patients of controlled group were treated by Calcium Carbonate and Vitamin D3chewable tablets, observing for3month and four weeks made up of a course of treatment.The observed indexes included curative effect indexes,such as clinical symptoms, blood glucose,HbAlc,serum Calcium and Phosphate, Estradiol, Testosterone, IL-6, urinary calcium, BMD and so on.The complete data carries on statistics analysis by the SPSS16.0statistics software.
Results:The study included type-2diabetic patients with50cases.25cases of treated group, while25cases of controlled group. Prior treatment,the gender, age, course of disease of the two groups patients had no differeces.1. Symptoms and signs improvement:the treated group after treatment had a significant improvement. The symptoms improvement of the treated group was better than the controlled group (P<0.01).2.Blood glucose:The FBG, PBG of treated group and controlled group were significantly lower(P<0.01); After treatment, the FBG of the treated group had a significant difference than controlled group(P<0.01).The PBG of treated group also had a significant difference than controlled group (P<0.05), The HbAlc of treated group also had a significant difference than controlled group (P<0.05).3. Bone mineral density:After treatment,the BMD of the treated group were significantly higher than controlled group(P <0.01).while the controlled group had no statistically significance(P>0.05).The BMD of the treated group had a significant difference than controlled group(P<0.05).4.Calcium and Phosphate:Serum calcium of the two groups were higher, but had no statistically significance(P>0.05).Serum phosphate of the two groups were lower, but had no statistically significance difference.Serum calcium and phosphate of the controlled group had no statistically significance difference(P>0.05).5.Hormone:In the male sufferer,after treatment,the E2of the treated group was visibly lower, had a significantly difference than controlled group(P<0.05), the T of the treated group was visibly higher, had a significantly difference than controlled group(P<0.01).The improvement of E2of the treated group had a significant difference than controlled group(P<0.05).the improvement of T of the treated group was better than the controlled group, but had no statistically significance difference(P>0.05).In the female sufferer, the E2of the treated group was visibly higher(P＜0.01), the T was visibly lower(P<0.01).The improvement of E2of the treated group was better than the controlled group(P<0.05), the improvement of T of the treated group was better than the controlled group, but had no statistically significance difference(P>0.05).6.IL-6:The IL-6of the treated group were also significantly improved(P<0.01), and had a significant difference than controlled group(P <0.05).7.Safety index:The routine blood/urine/feces test, and the liver and kidney function tests of treated group were within the normal range. Both groups had no unhealthy response.
Conclusion:Through the preliminary clinical study, Bone-vital-strong prescription has obvious curative effected in treating type-2diabetes with osteoporosis liver-kidney deficiency symptoms. From the angle of western medicine, it can reduced blood sugar and HbAlc, improve BMD, decrease the excretion of urinary calcium, and adjust hormone.And, most importantly,be safe and effective.lt is worth studying deeply and developing further.Remarkable results have been achieved by bone-vital-strong prescription that reducing blood and improved BMD.But because of my ability and conditions limited as an overseas student, there were small number of cases and simple observational items in this study. And further investigations is required.
方法：采用随机、对照的研究方法,将符合老年糖尿病合并骨质疏松症的患者50例,按1：1对照原则,随机分为对照组和治疗组。在基础治疗和西药常规降糖治疗的基础上,对照组给予钙尔奇D片600mg,每日1次；治疗组给予补肾化瘀壮骨方中药水煎剂,每日1剂,分早晚两次服用。以4周为1个疗程,观察3个疗程。治疗前后两组分别评价其临床症状、体征的变化,治疗前后观测血糖、糖化血红蛋白,骨密度、血清钙、磷,雌二醇、睾酮,白介素-6等指标。全部数据以SPSS16.0统计软件进行统计学分析。
结果：治疗前两组的性别、年龄、病程等基线数据经统计学处理无显着性差异,有可比性(P>0.05)。①对症状体征的改善作用：治疗组患者治疗后中医证候有明显改善,且治疗组改善情况明显优于对照组,有显著性差异(P<0.01)。②降糖效果：治疗后两组患者空腹血糖、餐后血糖均明显降低,与治疗前比较均有显着性差异(P<0.01)；组间比较治疗组空腹血糖改善较对照组有显著性差异(P<0.01),治疗组餐后血糖、糖化血红蛋白改善较对照组有差异(P<0.05)。③改善骨密度(BMD)：治疗后治疗组患者BMD均明显升高,较治疗前有显著性差异(P<0.01)；对照组较治疗前无明显差异(P>0.05)。组间比较治疗组BMD的改善较对照组有差异(P<0.05)。④对血钙、血磷的影响：治疗前两组血钙、血磷比较,无明显差异(P>0.05),具有可比性。治疗后两组患者血钙均有所升高,但差异无统计学意义(P>0.05)；治疗后两组患者血磷均有所降低,但差异无统计学意义(P>0.05)；治疗组血钙、血磷的变化较对照组无显著性差异(P>0.05)。⑤性激素水平：治疗后治疗组男性患者雌二醇(E2)水平下降,雄激素(T)水平升高,较治疗前有显著性差异(P<0.01)。组间比较,治疗组E2水平改善较对照组有差异(P<0.05)；治疗组T水平升高较对照组无差异(P>0.05)。治疗后治疗组女性患者E2水平升高,T水平降低,较治疗前均有显著性差异(P<0.01)。组间比较,治疗组E2水平升高较对照组有差异(P<0.05),T水平降低较对照组无显著性差异(P>0.05)。⑥对白介素-6(IL-6)的影响：治疗后治疗组患者IL-6较治疗前改善有显著性差异(P<0.01)；组间比较治疗组IL-6改善较对照组有差异(P<0.05)。⑦安全性指标：治疗组患者血、尿、粪常规及肝肾功能检查均在正常范围。两组均未见不良反应。
结论：从初步临床研究来看,补肾化瘀壮骨法治疗2型糖尿病骨质疏松症肾虚血瘀证,可明显改善患者的临床症状；在西医学指标方面,可以降低血糖、糖化血红蛋白,改善骨密度,调节性激素水平,且无肝肾功能损害,治疗本病安全、有效,有广泛的应用前景。但由于本人为境外学生,能力和条件限制,本研究病例数相对较少,今后需进一步深入研究。
Purpose:To discuss the understanding of Traditional Chinese Medicine about type-2diabetes with osteoporosis, using the therapy of renal-vital-reinforce and bone-vital-strong prescription to treat type-2diabetes with osteoporosis.To observe the therapeutic efficacy of this prescription in treating type-2diabetes with osteoporosis liver-kidney deficiency symptoms by the indexes such as clinical symptoms,hormones,cytokines,bone mineral density.Then evaluate its curative effect and safety, so as to guide its clinical application
Methods:A randomized,controlled trial was conducted.The patients of type-2diabetes with osteoporosis were randomly classified into two groups according to1:1paired matched.On the basic of normal treatment and western medicine, the patients of treated group were treated by Chinese medicine while the patients of controlled group were treated by Calcium Carbonate and Vitamin D3chewable tablets, observing for3month and four weeks made up of a course of treatment.The observed indexes included curative effect indexes,such as clinical symptoms, blood glucose,HbAlc,serum Calcium and Phosphate, Estradiol, Testosterone, IL-6, urinary calcium, BMD and so on.The complete data carries on statistics analysis by the SPSS16.0statistics software.
Results:The study included type-2diabetic patients with50cases.25cases of treated group, while25cases of controlled group. Prior treatment,the gender, age, course of disease of the two groups patients had no differeces.1. Symptoms and signs improvement:the treated group after treatment had a significant improvement. The symptoms improvement of the treated group was better than the controlled group (P<0.01).2.Blood glucose:The FBG, PBG of treated group and controlled group were significantly lower(P<0.01); After treatment, the FBG of the treated group had a significant difference than controlled group(P<0.01).The PBG of treated group also had a significant difference than controlled group (P<0.05), The HbAlc of treated group also had a significant difference than controlled group (P<0.05).3. Bone mineral density:After treatment,the BMD of the treated group were significantly higher than controlled group(P <0.01).while the controlled group had no statistically significance(P>0.05).The BMD of the treated group had a significant difference than controlled group(P<0.05).4.Calcium and Phosphate:Serum calcium of the two groups were higher, but had no statistically significance(P>0.05).Serum phosphate of the two groups were lower, but had no statistically significance difference.Serum calcium and phosphate of the controlled group had no statistically significance difference(P>0.05).5.Hormone:In the male sufferer,after treatment,the E2of the treated group was visibly lower, had a significantly difference than controlled group(P<0.05), the T of the treated group was visibly higher, had a significantly difference than controlled group(P<0.01).The improvement of E2of the treated group had a significant difference than controlled group(P<0.05).the improvement of T of the treated group was better than the controlled group, but had no statistically significance difference(P>0.05).In the female sufferer, the E2of the treated group was visibly higher(P＜0.01), the T was visibly lower(P<0.01).The improvement of E2of the treated group was better than the controlled group(P<0.05), the improvement of T of the treated group was better than the controlled group, but had no statistically significance difference(P>0.05).6.IL-6:The IL-6of the treated group were also significantly improved(P<0.01), and had a significant difference than controlled group(P <0.05).7.Safety index:The routine blood/urine/feces test, and the liver and kidney function tests of treated group were within the normal range. Both groups had no unhealthy response.
Conclusion:Through the preliminary clinical study, Bone-vital-strong prescription has obvious curative effected in treating type-2diabetes with osteoporosis liver-kidney deficiency symptoms. From the angle of western medicine, it can reduced blood sugar and HbAlc, improve BMD, decrease the excretion of urinary calcium, and adjust hormone.And, most importantly,be safe and effective.lt is worth studying deeply and developing further.Remarkable results have been achieved by bone-vital-strong prescription that reducing blood and improved BMD.But because of my ability and conditions limited as an overseas student, there were small number of cases and simple observational items in this study. And further investigations is required.
引文
[1]Soto N, Pruzzo R,Eyzaguirre F,etal.Bone mass and sex steroids in postmenarcheal adolescents and adult women with type 1 diabetes mellitus[J].J Diabetes Complications,2011,25(1):19-24.
[2]PetitMA,PaudelML,TaylorBC,etal.Boneinass and strength in older men will type 2 diabetes:the Osteoporotic Fractures in Men Study[J].J Bone Miner Res,2010,25(2):285-291.
[3]Yaturu S,Humphrey S,Landry C,etal.Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes[J].Med SciMoult,20o9,15(1):CR5-CR9.
[4]Yamamoto M,Yamaguchi T,Yamauchi M,et.Diabetic patients have an increased risk of vertebral actures independent of BMD or diabetic complications[J]. J Bone Miner Res,2009,24 (4):702-709.
[5]World Health Organization.
[6]International Diabetes Federation.
[7]Cryer PE.and Childs SP.American Diabetes Association Complete guide to diabetes. American Diabetes Association. U.S.A.1996, p8-29.
[8]叶任高.内科学[M].北京：人民卫生出版社,2000：798-810.
[9]黄伯超.潘文涵.李隆安.高美丁.曾明淑.李兰.萧信云.洪永泰(1998)国民营养健康状况变迁调查报告.台湾民众重要相关疾病糖尿病之状况.1993-1996年.
[10]陈纪桦.血糖调节机制及功效评估.食品工业,1992,34(6)：2-18.
[11]裴魡.胰岛素敏感度,葡萄糖敏感度及贝它细胞分泌功能在第二型糖尿病致病机转所扮演的角色[J].中华民国内分泌暨糖尿病学会会讯,1996,4(36)：4-7
[12]Kahn C.R.Flier,J. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M. & Roth, J.(1976).The syndromes of insulin resistance and acanthosisnigricans. Insulin-receptor disorders in man. N Engl J Med 294(14):739-45.
[13]Olefsky, J., Farquhar, J. W.&Reaven, G. (1973).Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects.Diabetes 2,2 (7):507-13.
[14]柯雅妍.Exploring the Relationship and Discourse of Diabetes Mellitus in the Traditional Chinese Medicine and Western Medicine.2007.7:1-33.
[15]DeFronzo RA (1998) Current therapy of diabetes mellitus.pp 1-4. Mobsy. U.S.A.
[16]Oberly LW (1988) Free radicals and diabetes. Free RadicBiol Med 5:113-124. (Baynes JW (1991) Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-411.
[17]Kahn,S.E. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 17;108Suppl 6a:2S-8S. (2000)
[18]The American Diabetes Association.(1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.20(7):1183-97.
[19]谢昌勋.糖尿病最新诊断标准与分类：美国糖尿病学会1997年报告[J].国防医学,30(6)：468-473.
[20]Amigo,L., Mendoza,H.,Zanlundo, S., Miquel, J. F., Rigotti, A., Gonzalz, S. & Nervi, F. (1999) Enrichement of canalicular membrane with cholesterol and sphingomylin prevents bile salt-induced hepatic damage. J. Lipid Res.40:533-542.
[21]陈国群.最新糖尿病精要[M].台北市：艺轩图书出版社.
[22]Mai Su-Ying. Yang Shwu-Huey Ph.D, Effects of High Dietary Fiber Intake on Plasma Lipid Profile in Type 2 Diabetic Patients (M),2003,12(3):3-12.
[23]徐焱.糖尿病患者合并高血压对降压药物的选择和应用[J],中国糖尿病杂志,2006,14(6)：405-407.
[24]高玉芬.Ⅱ型糖尿病患者骨密度变化.中华骨科杂志.1995,15(5)：582.
[25]沈稚舟.糖尿病慢性并发症[M].上海：上海医科大学出版社.1999：1.
[26]孔令芳.老年糖尿病合并骨质疏松64例骨密度检验及临床分析[J].中国实用内科杂志1995,15(3)：153.
[27]Beresford JN,Ganagher JA,Poser JW,et al.Prodwcfion of osteocalcin by human bone ceUs in vitro.-offects 1.25(OH)2D3,24,25(OH)2D3,parathyroid hormone,and glucocorticx)ids.Metab Bone Disrelat Res 1984,5(5):229-234.
[28]Price PA,Rthemore JG,Deftos LJ,et al.New biochemical marker for bo ne metabo lism:measure by radioimmunoassay of bone GLA protein in the plasma of norrllal subjects and patients with bone disease.Clln Invest 1980,66(5):878-883.
[29]Corpas E,Harman SM,Blackman M R,et al.Serum IGRbinding protein 3 is related to IGF-l.but not to spontaneous GH release in healthy oldman.Horm MetabRes 1992,24(11):543-545.
[30]Balint E,Szabo P,M arshall CF,et al.Glucose-induced inhibition of in vitro bone mineral-afion.Bone 2001,28(1):21-28.
[31]Takagi M,Kasayam S,Yamam oto T,et al.Advanced glycation end products stim ulate interleuk in-6 production by human bone derived cell.J Bone Miner Res 1997,12(3):439-443.
[32]Balint E,Szabo P,M arshall CF,et al.Glucose-induced inhibition of in vitro bone mineral-ation.Bone 2001,28(1):21-28.
[33]K ANABROCKI E L.HERM IDA R C,W RIGHT M,et al CircadJan variation of serum leptin in healthy and diabetic men.Chrono.biol Int 2001,18(2):273-283.
[34]Kanabrocki EL,Hermid RC,W right M,et al.Circadian variation of serunl leptin in healthy an d diabetic men.Chronobiol Zn 2000,18(2):273-283.
[35]范原,罗尧生,薛元明,等.男性糖尿病患者血清睾酮变化与糖尿病微血管病变的关系[J].云南医药,2000,21(2)：84-85.
[36]张婷容,韩梅清.老年2型糖尿病与骨质疏松的相关因素分析[J].广东医学,2006,27(1)：107-10820.
[37]胡彩虹,倪安民,何继瑞.一氧化氮与2型糖尿病患者骨代谢变化的关系[J].中国老年学杂志,2004,7(24)：585-586.
[38]王刚锐,董天华.原发性骨质疏松患者骨组织肿瘤坏死因子和白细胞介素-6的活性变化[J].中华实验外科杂志,1998,15：236-237.
[39]Suda T,Oelzner P,Hein GY.Modulmion of osteoclast differentiation by local factors.Bone,2004,26(4): 875-879.
[40]Kanabrocki EL,Hermid RC,W right M,et al.Circadian variation of serunl leptin in healthy an d diabetic men.Chronobiol Zn 2000,18(2):273-283.
[41]范原,罗尧生,薛元明,等.男性糖尿病患者血清睾酮变化与糖尿病微血管病变的关系[J].云南医药,2000,21(2)：84-85.
[42]张婷容,韩梅清.老年2型糖尿病与骨质疏松的相关因素分析[J].广东医学,2006,27(1)：107-10820.
[43]胡彩虹,倪安民,何继瑞.一氧化氮与2型糖尿病患者骨代谢变化的关系[J].中国老年学杂志,2004,7(24)：585-586.
[44]王刚锐,董天华.原发性骨质疏松患者骨组织肿瘤坏死因子和白细胞介素-6的活性变化[J].中华实验外科杂志,1998,15：236-237.
[45]Suda T,Oelzner P,Hein GY.Modulmion of osteoclast differentiation by local factors.Bone,2004,26(4): 875-879.
[46]张晓君,吴志平.糖尿病骨质疏松症的中医认识[J].现代中西医结合杂志,2004,13(6)：30
[47]李晶,赵莉娟,陕艳.糖尿病骨质疏松的中医治疗思路与方法探讨[J].山西中医学院学报,2002,3(3)：62
[48]徐立群,张荣华,蔡宇,等.糖尿病骨质疏松症中医病机和治则探讨[J].四川中医,2005,23(2)：27-28
[49]张亮.虎潜丸加减治疗糖尿病性骨质疏松症56例[J].河北中医,2003,25(3)：41.
[50]卫明,郭明昌.蚁菟降糖液治疗2型糖尿病性骨质疏松症的临床研究[J].中国医药学报,1996,11(5)：51.
[51]毕红征,黄国钧.益肾胶囊对糖尿病大鼠血糖及骨代谢的影响[J].中国药理与临床,2004,20(3)：32-33.
[52]刘素荣.肾胶囊治疗糖尿病骨质疏松症症临床与实验研究[J].山东中医药大学学报,2002,26(1)：24.
[53]王芳,李恩,孙树汉.补肾方药对糖尿病大鼠骨密度的影响及作用机制的研究[J].中华实用中西医杂志,2004,17(20)：3089-3092.
[2]PetitMA,PaudelML,TaylorBC,etal.Boneinass and strength in older men will type 2 diabetes:the Osteoporotic Fractures in Men Study[J].J Bone Miner Res,2010,25(2):285-291.
[3]Yaturu S,Humphrey S,Landry C,etal.Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes[J].Med SciMoult,20o9,15(1):CR5-CR9.
[4]Yamamoto M,Yamaguchi T,Yamauchi M,et.Diabetic patients have an increased risk of vertebral actures independent of BMD or diabetic complications[J]. J Bone Miner Res,2009,24 (4):702-709.
[5]World Health Organization.
[6]International Diabetes Federation.
[7]Cryer PE.and Childs SP.American Diabetes Association Complete guide to diabetes. American Diabetes Association. U.S.A.1996, p8-29.
[8]叶任高.内科学[M].北京：人民卫生出版社,2000：798-810.
[9]黄伯超.潘文涵.李隆安.高美丁.曾明淑.李兰.萧信云.洪永泰(1998)国民营养健康状况变迁调查报告.台湾民众重要相关疾病糖尿病之状况.1993-1996年.
[10]陈纪桦.血糖调节机制及功效评估.食品工业,1992,34(6)：2-18.
[11]裴魡.胰岛素敏感度,葡萄糖敏感度及贝它细胞分泌功能在第二型糖尿病致病机转所扮演的角色[J].中华民国内分泌暨糖尿病学会会讯,1996,4(36)：4-7
[12]Kahn C.R.Flier,J. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M. & Roth, J.(1976).The syndromes of insulin resistance and acanthosisnigricans. Insulin-receptor disorders in man. N Engl J Med 294(14):739-45.
[13]Olefsky, J., Farquhar, J. W.&Reaven, G. (1973).Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects.Diabetes 2,2 (7):507-13.
[14]柯雅妍.Exploring the Relationship and Discourse of Diabetes Mellitus in the Traditional Chinese Medicine and Western Medicine.2007.7:1-33.
[15]DeFronzo RA (1998) Current therapy of diabetes mellitus.pp 1-4. Mobsy. U.S.A.
[16]Oberly LW (1988) Free radicals and diabetes. Free RadicBiol Med 5:113-124. (Baynes JW (1991) Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-411.
[17]Kahn,S.E. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 17;108Suppl 6a:2S-8S. (2000)
[18]The American Diabetes Association.(1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.20(7):1183-97.
[19]谢昌勋.糖尿病最新诊断标准与分类：美国糖尿病学会1997年报告[J].国防医学,30(6)：468-473.
[20]Amigo,L., Mendoza,H.,Zanlundo, S., Miquel, J. F., Rigotti, A., Gonzalz, S. & Nervi, F. (1999) Enrichement of canalicular membrane with cholesterol and sphingomylin prevents bile salt-induced hepatic damage. J. Lipid Res.40:533-542.
[21]陈国群.最新糖尿病精要[M].台北市：艺轩图书出版社.
[22]Mai Su-Ying. Yang Shwu-Huey Ph.D, Effects of High Dietary Fiber Intake on Plasma Lipid Profile in Type 2 Diabetic Patients (M),2003,12(3):3-12.
[23]徐焱.糖尿病患者合并高血压对降压药物的选择和应用[J],中国糖尿病杂志,2006,14(6)：405-407.
[24]高玉芬.Ⅱ型糖尿病患者骨密度变化.中华骨科杂志.1995,15(5)：582.
[25]沈稚舟.糖尿病慢性并发症[M].上海：上海医科大学出版社.1999：1.
[26]孔令芳.老年糖尿病合并骨质疏松64例骨密度检验及临床分析[J].中国实用内科杂志1995,15(3)：153.
[27]Beresford JN,Ganagher JA,Poser JW,et al.Prodwcfion of osteocalcin by human bone ceUs in vitro.-offects 1.25(OH)2D3,24,25(OH)2D3,parathyroid hormone,and glucocorticx)ids.Metab Bone Disrelat Res 1984,5(5):229-234.
[28]Price PA,Rthemore JG,Deftos LJ,et al.New biochemical marker for bo ne metabo lism:measure by radioimmunoassay of bone GLA protein in the plasma of norrllal subjects and patients with bone disease.Clln Invest 1980,66(5):878-883.
[29]Corpas E,Harman SM,Blackman M R,et al.Serum IGRbinding protein 3 is related to IGF-l.but not to spontaneous GH release in healthy oldman.Horm MetabRes 1992,24(11):543-545.
[30]Balint E,Szabo P,M arshall CF,et al.Glucose-induced inhibition of in vitro bone mineral-afion.Bone 2001,28(1):21-28.
[31]Takagi M,Kasayam S,Yamam oto T,et al.Advanced glycation end products stim ulate interleuk in-6 production by human bone derived cell.J Bone Miner Res 1997,12(3):439-443.
[32]Balint E,Szabo P,M arshall CF,et al.Glucose-induced inhibition of in vitro bone mineral-ation.Bone 2001,28(1):21-28.
[33]K ANABROCKI E L.HERM IDA R C,W RIGHT M,et al CircadJan variation of serum leptin in healthy and diabetic men.Chrono.biol Int 2001,18(2):273-283.
[34]Kanabrocki EL,Hermid RC,W right M,et al.Circadian variation of serunl leptin in healthy an d diabetic men.Chronobiol Zn 2000,18(2):273-283.
[35]范原,罗尧生,薛元明,等.男性糖尿病患者血清睾酮变化与糖尿病微血管病变的关系[J].云南医药,2000,21(2)：84-85.
[36]张婷容,韩梅清.老年2型糖尿病与骨质疏松的相关因素分析[J].广东医学,2006,27(1)：107-10820.
[37]胡彩虹,倪安民,何继瑞.一氧化氮与2型糖尿病患者骨代谢变化的关系[J].中国老年学杂志,2004,7(24)：585-586.
[38]王刚锐,董天华.原发性骨质疏松患者骨组织肿瘤坏死因子和白细胞介素-6的活性变化[J].中华实验外科杂志,1998,15：236-237.
[39]Suda T,Oelzner P,Hein GY.Modulmion of osteoclast differentiation by local factors.Bone,2004,26(4): 875-879.
[40]Kanabrocki EL,Hermid RC,W right M,et al.Circadian variation of serunl leptin in healthy an d diabetic men.Chronobiol Zn 2000,18(2):273-283.
[41]范原,罗尧生,薛元明,等.男性糖尿病患者血清睾酮变化与糖尿病微血管病变的关系[J].云南医药,2000,21(2)：84-85.
[42]张婷容,韩梅清.老年2型糖尿病与骨质疏松的相关因素分析[J].广东医学,2006,27(1)：107-10820.
[43]胡彩虹,倪安民,何继瑞.一氧化氮与2型糖尿病患者骨代谢变化的关系[J].中国老年学杂志,2004,7(24)：585-586.
[44]王刚锐,董天华.原发性骨质疏松患者骨组织肿瘤坏死因子和白细胞介素-6的活性变化[J].中华实验外科杂志,1998,15：236-237.
[45]Suda T,Oelzner P,Hein GY.Modulmion of osteoclast differentiation by local factors.Bone,2004,26(4): 875-879.
[46]张晓君,吴志平.糖尿病骨质疏松症的中医认识[J].现代中西医结合杂志,2004,13(6)：30
[47]李晶,赵莉娟,陕艳.糖尿病骨质疏松的中医治疗思路与方法探讨[J].山西中医学院学报,2002,3(3)：62
[48]徐立群,张荣华,蔡宇,等.糖尿病骨质疏松症中医病机和治则探讨[J].四川中医,2005,23(2)：27-28
[49]张亮.虎潜丸加减治疗糖尿病性骨质疏松症56例[J].河北中医,2003,25(3)：41.
[50]卫明,郭明昌.蚁菟降糖液治疗2型糖尿病性骨质疏松症的临床研究[J].中国医药学报,1996,11(5)：51.
[51]毕红征,黄国钧.益肾胶囊对糖尿病大鼠血糖及骨代谢的影响[J].中国药理与临床,2004,20(3)：32-33.
[52]刘素荣.肾胶囊治疗糖尿病骨质疏松症症临床与实验研究[J].山东中医药大学学报,2002,26(1)：24.
[53]王芳,李恩,孙树汉.补肾方药对糖尿病大鼠骨密度的影响及作用机制的研究[J].中华实用中西医杂志,2004,17(20)：3089-3092.